Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.

<h4>Background</h4>Exposure to risk factors such as hypertension or hypercholesterolemia decreases the bioavailability of endothelium-derived nitric oxide (NO) and impairs endothelium-dependent vasodilation. Recently, a circulating endogenous NO synthase inhibitor, asymmetric dimethylarginine (ADMA)... View More